Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 17 2022 - 4:30PM
Business Wire
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery, and diagnostic solutions to the
pharmaceutical, biotechnology, and life sciences industries,
announced today that it will participate in the KeyBanc Capital
Markets Life Sciences & MedTech Investor Forum. Management will
present virtually at 9:00 a.m. EDT on Tuesday, March 22, 2022.
A live audio webcast will be available on the Company’s website
at www.stevanatogroup.com under the "Investors" section of the
website. A replay will be available for approximately 90 days after
the event.
Forward-Looking Statements This press release may contain
certain forward-looking statements which include, or may include,
words such as “will”, "believe", "future", "expect", "foreseeable",
"expected", "to be", "estimated", "assumes", "would provide", and
other similar expressions (or their negative). Forward-looking
statements contained in this press release include, but are not
limited to, statements about our participation in the KeyBanc
Capital Markets Life Sciences & MedTech Investor Forum.
The forward-looking statements in this press release are based
on numerous assumptions regarding the Company’s present and future
business strategies and the environment in which the Company will
operate in the future. These forward-looking statements speak only
as at their dates. Stevanato Group undertakes no obligation to
update any forward-looking statement or statements to reflect
events or circumstances after the date on which such statement is
made or to reflect the occurrence of unanticipated events. New
factors emerge from time to time, and it is not possible to predict
all of these factors. Further, Stevanato Group cannot assess the
impact of each such factor on our business or the extent to which
any factor, or combination of factors, may cause actual results to
be materially different from those contained in any forward-looking
statements. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision.
About Stevanato Group Founded in 1949, Stevanato Group is
a leading global provider of drug containment, drug delivery and
diagnostic solutions to the pharmaceutical, biotechnology and life
sciences industries. The Group delivers an integrated, end-to-end
portfolio of products, processes and services that address customer
needs across the entire drug life cycle at each of the development,
clinical and commercial stages. Stevanato Group’s core capabilities
in scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients.
For more information, please visit www.stevanatogroup.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220317005923/en/
Media Stevanato Group media@stevanatogroup.com
Investor Relations Lisa Miles
lisa.miles@stevanatogroup.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Sep 2023 to Sep 2024